title: Altered insulin receptor processing and function in scrapie-infected neuroblastoma cell lines.
abstract: The underlying neurochemical changes contributing to prion-induced neurodegeneration remain largely unknown. This study shows that scrapie infection induced a 2-fold increase of insulin receptor (IR) protein and aberrantly processed IR beta-chain in scrapie-infected N2a neuroblastoma cells (ScN2a) as measured by Western blot of immunoprecipitated IR, in the absence of increased IR mRNA. Elevated IR protein level was further confirmed in an independently scrapie-infected neuroblastoma cell line N1E-115 (ScN1E-115). Proliferation studies showed that the increased IR level in ScN2a did not result in an increased insulin-mediated cell growth compared to normal N2a cells. Binding studies indicated that this apparent paradox was due to a 65% decrease in specific [(125)I]insulin binding sites in ScN2a when compared to the amount of immunoreactive IR, although the IR binding affinity was unchanged. Analysis of insulin stimulated IR tyrosine phosphorylation showed a slight but not significant reduction in ScN2a, when related to the increased level of immunoreactive IR. However, comparing the IR tyrosine phosphorylation to the loss of binding sites in ScN2a, we demonstrated an increased IR tyrosine phosphorylation of the remaining functional IR. In addition to these differences in IR properties, the basal extracellular signal regulated kinase-2 (ERK2) phosphorylation detected by Western blot, was significantly elevated and the insulin stimulated ERK2 phosphorylation was subsequently decreased in ScN2a. Together, these data show that scrapie infection affects the level and processing of the IR and signal transduction mediated by the IR in neuroblastoma cells, as well as induces an elevated basal ERK2 phosphorylation. Aberrant regulation of neuroprotective receptors may contribute to neurodegeneration in prion diseases.
authors.affiliation: Department of Neurochemistry and Neurotoxicology, University of Stockholm, Svante Arrhenius v. 21A, S-10691 Stockholm, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Ostlund
authors.forename: H
authors.initials: H
authors.lastname: Lindegren
authors.forename: C
authors.initials: C
authors.lastname: Pettersson
authors.forename: K
authors.initials: K
authors.lastname: Bedecs
mesh_terms: D000818:Animals; D015153:Blotting, Western; D002455:Cell Division / Q000187:drug effects; D015870:Gene Expression / Q000502:physiology; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D007457:Iodine Radioisotopes; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D009410:Nerve Degeneration / Q000378:metabolism / Q000503:physiopathology; D009447:Neuroblastoma; D010766:Phosphorylation; D011328:Prions / Q000378:metabolism; D011972:Receptor, Insulin / Q000032:analysis / Q000235:genetics* / Q000378:metabolism*; D012608:Scrapie / Q000378:metabolism* / Q000503:physiopathology*; D014407:Tumor Cells, Cultured; D014443:Tyrosine / Q000378:metabolism
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D007457:Iodine Radioisotopes; D011328:Prions; D014443:Tyrosine; D011972:Receptor, Insulin; D019950:Mitogen-Activated Protein Kinase 1